Trelstar® 11.25 mg
3-month Trelstar 11.25 mg maintains testosterone levels similar to those achieved with surgical castration.
- Mean testosterone concentrations between months 2 and 9 did not exceed 12.4 ng/dL in patients treated with Trelstar 11.25 mg4
- 97.7% of 3-month Trelstar 11.25 mg - treated patients achieved castrate level of testosterone by Day 291
- Maintenance of castration levels during months 2 through 9 was found in 94.4% of patients treated with Trelstar 11.25 mg1
*SEM=Standard error of the mean.
†At Day 0; at Day 253, n=142 for Trelstar® 3.75 mg and 149 for Trelstar® 11.25 mg.
Based on a multicenter, randomized, controlled clinical trial comparing Trelstar® 11.25 mg to Trelstar® 3.75 mg (active comparator) in patients with advanced (stage C/D) prostate cancer (n=346). Investigators and patients were blinded to the treatment assignment at time of enrollment.
3-month Trelstar 11.25 mg reliably suppresses prostate specific antigen.4
- Prostate-specific antigen (PSA) levels were reduced by 97% through month 9.4
*Based on a multicenter, randomized, controlled clinical trial comparing Trelstar® 11.25 mg to Trelstar® 3.75 mg (active comparator) in patients with advanced (stage C/D) prostate cancer (n=346). Investigators and patients were blinded to the treatment assignment at time of enrollment.
Easy Preparation, Administration, and Disposal with MIXJECT® Delivery System
- Low incidence of injection site pain (4.0%)1
- The only reported administration site reaction occurring in >1% of patients (n=174)1
- No refrigeration required
- IM administration
- Trelstar® full Prescribing Information, Watson Pharma, Inc.
- Data on file, Watson Pharma, Inc. DEB-TRI6M-301 Clinical Study Report, May 2008.
- Lundström EA, Rencken RK, van Wyk JH, et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. Clin Drug Investig. 2009;29:757-765.
- Data on file. Watson Pharma, Inc. DEB-96-TRI-01 (first phase) Clinical Study Report; July 1999.
- Data on file. Watson Pharma, Inc. DEB-96-TRI-01 (second phase) Clinical Study Report; June 1999.
- Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000;56:1021-1024.
- Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol. 2007;178:1290-1295.
- Heyns CF, Simonin M-P, Grosgurin P, Schall R, Porchet HC. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU International. 2003;92:226-231.
Trelstar® is indicated for the palliative treatment of advanced prostate cancer.
Important Safety Information
The most commonly reported adverse events associated with the use of Trelstar® 22.5 mg included hot flushes (71.7%), erectile dysfunction (10.0%), and testicular atrophy (7.5%) • The most commonly reported adverse events associated with the use of Trelstar® 3.75 mg/Trelstar® 11.25 mg included hot flushes (58.6%/73.0%), skeletal pain (12.1%/13.2%), impotence (7.1%/2.3%), headache (5.0%/6.9%), leg pain (2.1%/5.2%), and edema in legs (0.0%/6.3%) • Trelstar® is contraindicated in women who are or may become pregnant as well as patients who are hypersensitive to triptorelin, other GnRH agonists, or GnRH • Anaphylactic shock, hypersensitivity, and angioedema related to triptorelin administration have been reported • Trelstar® causes an initial transient increase in testosterone levels. Patients may experience the onset or exacerbation of symptoms during this period, including bone pain, neuropathy, hematuria, urethral or bladder outlet obstruction, or spinal cord compression that may contribute to weakness or paralysis with or without fatal complications. Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely observed. Hyperglycemia and an increased risk of developing diabetes, as well as increased risk of myocardial infarction, sudden cardiac death, and stroke have been reported in men receiving GnRH analogs. Patients should be monitored for blood glucose level and cardiovascular disease, and managed according to current clinical practice
MIXJECT® is a registered trademark of Medimop Medical Projects Ltd.